Literature DB >> 10201651

Are randomized control trial outcomes influenced by the inclusion of a placebo group?: a systematic review of nonsteroidal antiinflammatory drug trials for arthritis treatment.

P A Rochon1, M A Binns, J A Litner, G M Litner, M S Fischbach, D Eisenberg, T J Kaptchuk, W B Stason, T C Chalmers.   

Abstract

Placebo groups are often included in randomized control trials evaluating drug therapy, yet we know little about the placebo effect. The purpose of our study was to evaluate how the presence of a placebo group in a randomized control trial (RCT) influences the patients' ratings of the efficacy of an active drug therapy and their reporting of its adverse effects. We identified studies published between 1966 and 1994 using MEDLINE. Randomized control trials evaluating acetylsalicylic acid, diclofenac, or indomethacin for the treatment of osteo or rheumatoid arthritis were included in our sample. Two investigators independently extracted data. Fifty-eight treatment arms met our inclusion criteria and were available for analysis. Twenty-five treatment arms evaluated a nonsteroidal antiinflammatory drug (NSAID) in placebo control trials and 33 in comparative trials. Using a logistic regression model to adjust for the differences between the evaluated drugs and between the types of arthritis, we found that patients receiving an NSAID in a placebo control trial were more likely to withdraw due to inefficacy (OR=1.3; 95% CI, 1.0 to 1.6; P=0.04). Using a similar model, withdrawals due to adverse effects were found to be more common when the NSAID was given in trials that did not include a placebo group (OR=1.5; 95% CI, 1.1 to 1.9; P=0.002) as were reports of cutaneous (OR=4.2; 95% CI, 1.7 to 9.9), gastrointestinal (OR=1.6; 95% CI, 1.3 to 2.0), and other types (OR=5.3; 95% CI, 3.8 to 7.4) of adverse effects. Although reports of central nervous system adverse effects were more frequent in the comparative trials, this difference was not significant. Including a placebo group in a RCT changes how patients rate the efficacy and adverse effects of their therapy. Our results highlight the need to consider the placebo effect in the design and analyses of clinical trials.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10201651     DOI: 10.1016/s0895-4356(98)00149-8

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  8 in total

Review 1.  Improving safety reporting from randomised trials.

Authors:  John P A Ioannidis; Joseph Lau
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 2.  Placebo effects: clinical aspects and neurobiology.

Authors:  Barry S Oken
Journal:  Brain       Date:  2008-06-21       Impact factor: 13.501

3.  Effect of information on reported adverse events in a placebo-controlled trial.

Authors:  Michael Ossege; Thomas Sycha; Martin Aigner; Leopold Schmetterer; Hans-Georg Eichler; Markus Müller; Franz König; Peter Bauer
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

4.  Diclofenac sodium topical solution with dimethyl sulfoxide, a viable alternative to oral nonsteroidal anti-inflammatories in osteoarthritis: review of current evidence.

Authors:  Philip Fuller; Sanford Roth
Journal:  J Multidiscip Healthc       Date:  2011-07-11

5.  Certainty of genuine treatment increases drug responses among intellectually disabled patients.

Authors:  Karin B Jensen; Irving Kirsch; Moa Pontén; Annelie Rosén; Kathy Yang; Randy L Gollub; Vincent des Portes; Ted J Kaptchuk; Aurore Curie
Journal:  Neurology       Date:  2017-04-19       Impact factor: 9.910

6.  Optimizing Aggregated N-Of-1 Trial Designs for Predictive Biomarker Validation: Statistical Methods and Theoretical Findings.

Authors:  Rebecca C Hendrickson; Ronald G Thomas; Nicholas J Schork; Murray A Raskind
Journal:  Front Digit Health       Date:  2020-08-28

7.  Association of trial registration with the results and conclusions of published trials of new oncology drugs.

Authors:  Nicolas Rasmussen; Kirby Lee; Lisa Bero
Journal:  Trials       Date:  2009-12-16       Impact factor: 2.279

8.  Detection of clinically relevant pain relief in cats with degenerative joint disease associated pain.

Authors:  M E Gruen; E Griffith; A Thomson; W Simpson; B D X Lascelles
Journal:  J Vet Intern Med       Date:  2014-02-10       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.